does glp 1 cause gastroparesis Implications of the glp-1 era on health New data links GLP-1 agonists

A 2023 study in Nature found that long COVID patients showed measurably altered cortisol levelsspecifically, significantly lower morning cortisol compared to recovered controls

10.1111/anu.12444 40 MalandrakisE.ExadactylosA.OlgaD.GolomazouE.KlaoudatosS.PanagiotaP

Overview of insulin: more than a hormone for controlling glucose level

Int J Androl 20:6169

Once youve completed an education course, youll be prepared to verify IDs, refuse service when necessary and know the signs of intoxication to look for so you can keep customers safe

Findings: RCTSURMOUNT-2 trial - Tirzepatide vs Placebo for Weight Loss in Diabetes, Lancet (2023) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=938 | length = 72 weeks) in overweight diabetics (mean BMI 36 | mean A1C 8.02%) Treatment: Tirzepatide 10 mg once weekly vs Tirzepatide 15 mg once weekly vs Placebo Primary outcome: Coprimary endpoints were the percent change in body weight from baseline and body weight reduction of 5% or higher Results: Primary outcome (% reduction in weight): Tirzepatide 10 mg - 12.8%, Tirzepatide 15 mg - 14.7%, Placebo - 3.2% (p 35 - 68.9% Randomized treatment groups Group 1 (374 patients): Tirzepatide titrated to the maximum tolerated dose of 10 mg or 15 mg once weekly Group 2 (376 patients): Semaglutide titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg once weekly Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the dose was increased by 2.5 mg every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was reached